Short Interest in Venus Concept Inc. (NASDAQ:VERO) Increases By 65.1%

Venus Concept Inc. (NASDAQ:VEROGet Rating) was the recipient of a large growth in short interest in May. As of May 15th, there was short interest totalling 611,600 shares, a growth of 65.1% from the April 30th total of 370,500 shares. Based on an average trading volume of 203,000 shares, the short-interest ratio is currently 3.0 days. Approximately 2.2% of the shares of the company are sold short.

Separately, Zacks Investment Research downgraded Venus Concept from a “buy” rating to a “hold” rating in a research note on Tuesday, March 22nd.

Shares of NASDAQ VERO opened at $0.76 on Friday. The company has a quick ratio of 2.61, a current ratio of 3.33 and a debt-to-equity ratio of 2.32. The stock has a market capitalization of $48.88 million, a price-to-earnings ratio of -2.01 and a beta of 2.28. The stock’s fifty day simple moving average is $1.08 and its 200 day simple moving average is $1.39. Venus Concept has a 52-week low of $0.62 and a 52-week high of $3.37.

Venus Concept (NASDAQ:VEROGet Rating) last issued its earnings results on Monday, March 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.04. The business had revenue of $32.63 million for the quarter, compared to analysts’ expectations of $32.50 million. Venus Concept had a negative return on equity of 71.57% and a negative net margin of 20.46%. During the same period in the previous year, the firm posted ($0.22) EPS. As a group, analysts anticipate that Venus Concept will post -0.29 earnings per share for the current year.

In other Venus Concept news, CEO Domenic Serafino bought 65,000 shares of the business’s stock in a transaction on Friday, May 20th. The shares were purchased at an average price of $0.75 per share, with a total value of $48,750.00. Following the purchase, the chief executive officer now directly owns 933,758 shares of the company’s stock, valued at $700,318.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stanley Tyler Hollmig bought 40,000 shares of the business’s stock in a transaction on Tuesday, May 24th. The shares were acquired at an average cost of $0.64 per share, for a total transaction of $25,600.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at $25,600. The disclosure for this purchase can be found here. Insiders have acquired a total of 115,000 shares of company stock worth $82,850 in the last ninety days. 44.07% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Divisadero Street Capital Management LP grew its holdings in shares of Venus Concept by 2.5% in the 1st quarter. Divisadero Street Capital Management LP now owns 1,100,000 shares of the company’s stock worth $1,573,000 after acquiring an additional 27,285 shares during the last quarter. Prelude Capital Management LLC grew its holdings in shares of Venus Concept by 73.4% during the first quarter. Prelude Capital Management LLC now owns 177,246 shares of the company’s stock valued at $253,000 after buying an additional 75,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Venus Concept by 2.3% during the first quarter. Vanguard Group Inc. now owns 1,121,558 shares of the company’s stock valued at $1,603,000 after buying an additional 25,630 shares in the last quarter. HighTower Advisors LLC purchased a new position in shares of Venus Concept during the first quarter valued at $31,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Venus Concept by 140.2% during the first quarter. Bank of New York Mellon Corp now owns 86,578 shares of the company’s stock valued at $124,000 after buying an additional 50,530 shares in the last quarter.

Venus Concept Company Profile (Get Rating)

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.

Read More

Receive News & Ratings for Venus Concept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venus Concept and related companies with MarketBeat.com's FREE daily email newsletter.